According to findings from two Phase III clinical trials, Botox proved to be successful as a treatment for people experiencing chronic migraines, said Allergan Inc, the global specialty pharmaceutical and medical technology company that offers patients products like the facial wrinkle-smoother.

A study on the effects of Botox on adults suffering from chronic migraines has been conducted. The patients were assigned to one of the two groups. Some were administered Botox, whereas the others were administered a placebo injection once every three months. Following the two treatment cycles, an initial analysis was carried out.

There were two different ways the effectiveness of the injection was evaluated: one - By the change in the number of headache episodes patients underwent during the trial period, and the other one – by the number of days headaches lasted over the same period of time.

In spite of failing to reach the goal in the first cycle of the trial, Botox treatments worked, in contrast with the placebo ones. The number of days in which headaches showed up in participants and the number of headache episodes that occurred declined.

Scott Whitcup, M.D., and Executive Vice President of Research & Development of the Botox distributor, said the company is “pleased with the top-line results of our Phase III clinical trials which show that BOTOX treatment provided benefit to these patients whose lives have been profoundly impacted by this severely debilitating condition.”

Extremely content with the outcome of the study, he added “it is gratifying to focus our research and development efforts on an indication that addresses such an important unmet medical need.”